Tim E. Hawkins

1.3k total citations · 1 hit paper
15 papers, 882 citations indexed

About

Tim E. Hawkins is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Tim E. Hawkins has authored 15 papers receiving a total of 882 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Tim E. Hawkins's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and S100 Proteins and Annexins (4 papers). Tim E. Hawkins is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and S100 Proteins and Annexins (4 papers). Tim E. Hawkins collaborates with scholars based in United States, Australia and New Zealand. Tim E. Hawkins's co-authors include Stephen E. Moss, David MacDonald, Ian W. Flinn, Samar Issa, John M. Burke, Peter Wood, Kathryn S. Kolibaba, David Simpson, Brad S. Kahl and Doreen M. Hallman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Tim E. Hawkins

15 papers receiving 866 citations

Hit Papers

Randomized trial of bendamustine-rituximab or R-CHOP/R-CV... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
    2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim E. Hawkins United States 11 614 497 320 221 137 15 882
Frédéric Gilles United States 12 353 0.6× 300 0.6× 202 0.6× 375 1.7× 35 0.3× 21 753
Beth Christian United States 18 682 1.1× 521 1.0× 404 1.3× 132 0.6× 172 1.3× 84 979
Yoshikazu Sasaki Japan 11 272 0.4× 184 0.4× 97 0.3× 94 0.4× 74 0.5× 23 491
Jeffrey Tang Canada 5 556 0.9× 353 0.7× 233 0.7× 194 0.9× 102 0.7× 8 714
S. Öhl Germany 13 378 0.6× 234 0.5× 264 0.8× 216 1.0× 84 0.6× 19 778
Alicja Gruszka Italy 20 380 0.6× 259 0.5× 378 1.2× 395 1.8× 58 0.4× 36 945
Michael Voralia Canada 11 309 0.5× 268 0.5× 263 0.8× 229 1.0× 35 0.3× 25 681
Xinyan Lu United States 20 271 0.4× 292 0.6× 313 1.0× 280 1.3× 41 0.3× 58 969
Jennifer E. Amengual United States 15 450 0.7× 408 0.8× 137 0.4× 574 2.6× 63 0.5× 87 1.1k
Jennifer Lauchle United States 13 83 0.1× 203 0.4× 181 0.6× 512 2.3× 104 0.8× 23 833

Countries citing papers authored by Tim E. Hawkins

Since Specialization
Citations

This map shows the geographic impact of Tim E. Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim E. Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim E. Hawkins more than expected).

Fields of papers citing papers by Tim E. Hawkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim E. Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim E. Hawkins. The network helps show where Tim E. Hawkins may publish in the future.

Co-authorship network of co-authors of Tim E. Hawkins

This figure shows the co-authorship network connecting the top 25 collaborators of Tim E. Hawkins. A scholar is included among the top collaborators of Tim E. Hawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim E. Hawkins. Tim E. Hawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2019). First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology. 37(12). 984–991. 166 indexed citations
2.
Kahl, Brad S., John M. Burke, Richard van der Jagt, et al.. (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood. 130. 484–484. 10 indexed citations
3.
Flinn, Ian W., Richard van der Jagt, Julie Chang, et al.. (2017). First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.. Journal of Clinical Oncology. 35(15_suppl). 7500–7500. 13 indexed citations
4.
Burke, John M., Brad S. Kahl, Peter Wood, et al.. (2016). Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 16(4). 182–190.e1. 14 indexed citations
5.
Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952. 419 indexed citations breakdown →
6.
7.
MacDonald, David, Richard van der Jagt, John M. Burke, et al.. (2013). Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.. Journal of Clinical Oncology. 31(15_suppl). 8565–8565. 2 indexed citations
8.
9.
10.
Song, Guojie, Siân E. Harding, Michael R. Duchen, et al.. (2002). Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin 6 null‐mutant mice. The FASEB Journal. 16(6). 622–624. 46 indexed citations
11.
Broady, Raewyn, et al.. (2000). Mycobacterium-Avium-Intracellulare Complex Infection Following 2-Chlorodeoxyadenosine Therapy For Hairy. Leukemia & lymphoma. 36(5-6). 639–642. 3 indexed citations
12.
Hawkins, Tim E., Christien J. Merrifield, & Stephen E. Moss. (2000). Calcium Signaling and Annexins. Cell Biochemistry and Biophysics. 33(3). 275–296. 50 indexed citations
13.
Kubista, Helmut, Tim E. Hawkins, Darshana Patel, Harry T. Haigler, & Stephen E. Moss. (1999). Annexin 5 mediates a peroxide-induced Ca2+ influx in B cells. Current Biology. 9(23). 1403–1408. 47 indexed citations
14.
Hawkins, Tim E., et al.. (1999). Immunological Development and Cardiovascular Function Are Normal in Annexin VI Null Mutant Mice. Molecular and Cellular Biology. 19(12). 8028–8032. 61 indexed citations
15.
Kubista, Helmut, Tim E. Hawkins, & Stephen E. Moss. (1998). Characterisation of calcium signalling in DT40 chicken B-cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1448(2). 299–310. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric Gilles Breakdown of academic impact, for papers by Beth Christian Breakdown of academic impact, for papers by Yoshikazu Sasaki Breakdown of academic impact, for papers by Jeffrey Tang Breakdown of academic impact, for papers by S. Öhl Breakdown of academic impact, for papers by Alicja Gruszka Breakdown of academic impact, for papers by Michael Voralia Breakdown of academic impact, for papers by Xinyan Lu Breakdown of academic impact, for papers by Jennifer E. Amengual Breakdown of academic impact, for papers by Jennifer Lauchle
Rankless by CCL
2026